Sinovac Biotech (SVA) 5.05 $SVA
Simavita Receives $1.37 Million Cash Payment Under R&D Tax Incentive Scheme
Marketwired - Thu Feb 05, 9:19AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to confirm the receipt of $1,370,468 under the Australian Government's Research and Development Tax Incentive Scheme. The claim covers the year ended 30 June 2014.
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Limited: Philippa Lewis Discusses the Abena Distribution Agreement and Appendix 4C
Marketwired - Wed Feb 04, 10:30AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to invite investors to listen to an audio recording of CEO, Ms. Philippa Lewis, providing further background to the Company's announcement released on January 29, 2015, entitled "Simavita signs up Danish distributor", and the Company's quarterly cash flow report, which was released on January 30, 2015.
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
ASX Appendix 4C for the Quarter Ended December 31, 2014
Marketwired - Fri Jan 30, 10:38AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to release its ASX Appendix 4C for the quarter ended December 31, 2014.
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Limited: Exclusive Agreement With Danish Distributor Executed and First Sales Recorded
Marketwired - Thu Jan 29, 10:41AM CST
Highlights:
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Limited: Release of Securities from Escrow
Marketwired - Tue Jan 20, 10:21AM CST
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) advises that a total of 1,155,298 warrants in the Company will be released from escrow on January 31, 2015.
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Appoints New Chairman
Marketwired - Wed Jan 07, 12:33PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to advise of the appointment of Mr. Michael Brown as a Director of the Company and as its Chairman of the Board.
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Limited: Record Sales Reported and Canadian Market Update
Marketwired - Tue Jan 06, 6:53PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) -
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Rubella Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 10:30PM CST
The report "Rubella Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rubella. Rubella is an illness that primarily affects the skin and lymph nodes. It is caused by the rubella virus which is typically transmitted by droplets from the nose or throat that others breathe in. Rubella is a significant health risk for pregnant women. But many children have such placid symptoms that they're unconscious of being infected. Most rubella infections today appear in young, non-immunized adults rather than in kids. Complete Report is Available @ http://www.reportsnreports.com/reports/321911...-2014.html .
GSK: 47.94 (+1.99), SVA: 5.05 (+0.06)
Influenza A Infections - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ntzfm/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Influenza A Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alios BioPharma - Autoimmune Technologies - Chimerix - ContraFect - Crucell - Cure Lab - CureVac - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Humabs BioMed - Immune Targeting Systems - Inovio Pharmaceuticals - Johnson & Johnson - Kyowa Hakko Kirin - MedImmune - Microbiotix - Microgen Scientific Industrial Company for Immunobiological Medicines - NanoViricides - SIGA Technologies - Sinovac Biotech - Theraclone Sciences - Vironova - Visterra - Vivaldi Biosciences - iBio For more information visit http://www.researchandmarkets.com/research/9n...nfluenza_a
JNJ: 99.62 (+1.18), INO: 6.80 (-0.15), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06)
Rabies - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3d4rd/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rabies - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology - Celltrion - Crucell - Humabs BioMed - Kaketsuken - Kamada - Medicago - Molecular Targeting Technologies - NanoViricides - Novavax - Sanofi Pasteur - Serum Institute of India - Sinovac Biotech - Trellis Bioscience - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/n3...s_pipeline
SVA: 5.05 (+0.06)
Diphtheria - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/c76242/diphtheria) has announced the addition of the "Diphtheria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology Co., Ltd - Biological E. Limited - GlaxoSmithKline plc - Green Cross Corporation - Indian Immunologicals Limited - LG Life Sciences, Ltd. - Novartis AG - Panacea Biotec Limited - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/c76242/diphtheria
GSK: 47.94 (+1.99), SVA: 5.05 (+0.06), NVS: 102.20 (-0.17)
Best Chinese Stocks For 2015
Reid K. - at Seeking Alpha - Sun Dec 28, 12:11PM CST
By Kate Wong Chinese stocks were among the best performing in 2014, growing by over 43% - a rise second only to Argentina's market. 2014 was also the year that the Chinese economy surpassed that of the United States', becoming the largest in the...
SNP: 80.13 (+0.33), SVA: 5.05 (+0.06)
Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5mrz3/hand_foot_and) has announced the addition of the "Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014" report to their offering. Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014" provides data on the Hand, Foot And Mouth Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hand, Foot And Mouth Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hand, Foot And Mouth Disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Hand, Foot And Mouth Disease Therapeutics Clinical Trials - Sinovac Biotech Co., Ltd. - Jiangxi Qingfeng Pharmaceutical Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Inviragen, Inc. (Inactive) Clinical Trial Overview of Top Institutes / Government - Jiangsu Provincial Center for Disease Control and Prevention - China Academy of Chinese Medical Sciences - Chinese Academy of Medical Sciences and Peking Union Medical College - Oxford University Clinical Research Unit - Capital Medical University - Cancer Institute and Hospital, Chinese Academy of Medical Sciences - Beijing University of Chinese Medicine - Zhengzhou University - Tianjin University of Traditional Chinese Medicine For more information visit http://www.researchandmarkets.com/research/k5...d_foot_and
SVA: 5.05 (+0.06)
Simavita Receives $1.37 Million Cash Payment Under R&D Tax Incentive Scheme
Marketwired - Thu Feb 05, 9:19AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to confirm the receipt of $1,370,468 under the Australian Government's Research and Development Tax Incentive Scheme. The claim covers the year ended 30 June 2014. SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Limited: Philippa Lewis Discusses the Abena Distribution Agreement and Appendix 4C
Marketwired - Wed Feb 04, 10:30AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to invite investors to listen to an audio recording of CEO, Ms. Philippa Lewis, providing further background to the Company's announcement released on January 29, 2015, entitled "Simavita signs up Danish distributor", and the Company's quarterly cash flow report, which was released on January 30, 2015. SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
ASX Appendix 4C for the Quarter Ended December 31, 2014
Marketwired - Fri Jan 30, 10:38AM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to release its ASX Appendix 4C for the quarter ended December 31, 2014. SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Limited: Exclusive Agreement With Danish Distributor Executed and First Sales Recorded
Marketwired - Thu Jan 29, 10:41AM CST
Highlights:
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Limited: Release of Securities from Escrow
Marketwired - Tue Jan 20, 10:21AM CST
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) advises that a total of 1,155,298 warrants in the Company will be released from escrow on January 31, 2015.
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Appoints New Chairman
Marketwired - Wed Jan 07, 12:33PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company"
is pleased to advise of the appointment of Mr. Michael Brown as a Director of the Company and as its Chairman of the Board. SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Simavita Limited: Record Sales Reported and Canadian Market Update
Marketwired - Tue Jan 06, 6:53PM CST
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) -
SV.VN: 0.500 (-0.050), SVA: 5.05 (+0.06)
Rubella Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 10:30PM CST
The report "Rubella Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rubella. Rubella is an illness that primarily affects the skin and lymph nodes. It is caused by the rubella virus which is typically transmitted by droplets from the nose or throat that others breathe in. Rubella is a significant health risk for pregnant women. But many children have such placid symptoms that they're unconscious of being infected. Most rubella infections today appear in young, non-immunized adults rather than in kids. Complete Report is Available @ http://www.reportsnreports.com/reports/321911...-2014.html .
GSK: 47.94 (+1.99), SVA: 5.05 (+0.06)
Influenza A Infections - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ntzfm/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Influenza A Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Alios BioPharma - Autoimmune Technologies - Chimerix - ContraFect - Crucell - Cure Lab - CureVac - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Humabs BioMed - Immune Targeting Systems - Inovio Pharmaceuticals - Johnson & Johnson - Kyowa Hakko Kirin - MedImmune - Microbiotix - Microgen Scientific Industrial Company for Immunobiological Medicines - NanoViricides - SIGA Technologies - Sinovac Biotech - Theraclone Sciences - Vironova - Visterra - Vivaldi Biosciences - iBio For more information visit http://www.researchandmarkets.com/research/9n...nfluenza_a
JNJ: 99.62 (+1.18), INO: 6.80 (-0.15), GSK: 47.94 (+1.99), SVA: 5.05 (+0.06)
Rabies - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/n3d4rd/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rabies - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology - Celltrion - Crucell - Humabs BioMed - Kaketsuken - Kamada - Medicago - Molecular Targeting Technologies - NanoViricides - Novavax - Sanofi Pasteur - Serum Institute of India - Sinovac Biotech - Trellis Bioscience - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/n3...s_pipeline
SVA: 5.05 (+0.06)
Diphtheria - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/c76242/diphtheria) has announced the addition of the "Diphtheria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Beijing Minhai Biotechnology Co., Ltd - Biological E. Limited - GlaxoSmithKline plc - Green Cross Corporation - Indian Immunologicals Limited - LG Life Sciences, Ltd. - Novartis AG - Panacea Biotec Limited - Sanofi - Sanofi Pasteur SA - Serum Institute of India Limited - Sinovac Biotech Ltd. - Takeda Pharmaceutical Company Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/c76242/diphtheria
GSK: 47.94 (+1.99), SVA: 5.05 (+0.06), NVS: 102.20 (-0.17)
Best Chinese Stocks For 2015
Reid K. - at Seeking Alpha - Sun Dec 28, 12:11PM CST
By Kate Wong Chinese stocks were among the best performing in 2014, growing by over 43% - a rise second only to Argentina's market. 2014 was also the year that the Chinese economy surpassed that of the United States', becoming the largest in the...
SNP: 80.13 (+0.33), SVA: 5.05 (+0.06)
Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5mrz3/hand_foot_and) has announced the addition of the "Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014" report to their offering. Hand, Foot And Mouth Disease Global Clinical Trials Review, H2, 2014" provides data on the Hand, Foot And Mouth Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hand, Foot And Mouth Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hand, Foot And Mouth Disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Hand, Foot And Mouth Disease Therapeutics Clinical Trials - Sinovac Biotech Co., Ltd. - Jiangxi Qingfeng Pharmaceutical Co., Ltd. - Jiangsu Kanion Pharmaceutical Co., Ltd. - Inviragen, Inc. (Inactive) Clinical Trial Overview of Top Institutes / Government - Jiangsu Provincial Center for Disease Control and Prevention - China Academy of Chinese Medical Sciences - Chinese Academy of Medical Sciences and Peking Union Medical College - Oxford University Clinical Research Unit - Capital Medical University - Cancer Institute and Hospital, Chinese Academy of Medical Sciences - Beijing University of Chinese Medicine - Zhengzhou University - Tianjin University of Traditional Chinese Medicine For more information visit http://www.researchandmarkets.com/research/k5...d_foot_and
SVA: 5.05 (+0.06)
